Stimulators of tissue-type plasminogen activator

Drugs of the Future

Volumn 21, Issue 3, 1996, Pages 291-299

  Kooistra, Teake ^a   Lansink, Mirian ^a,b   Emeis, Jef J ^a  

^a TNO   (Netherlands)

^b Netherlands Heart Foundation   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

4 [2 (5,6,7,8 TETRAHYDRO 5,5,8,8 TETRAMETHYL 2 NAPHTHYL) 1 PROPENYL]BENZOIC ACID; BENZODIAZEPINE DERIVATIVE; BUTYRIC ACID; CYCLIC AMP; PROTEIN KINASE C; RETINOIC ACID; RETINOID; TISSUE PLASMINOGEN ACTIVATOR; TRICHOSTATIN A; U 34599; U 46195; U 51477; UNCLASSIFIED DRUG;

ENDOTHELIUM CELL; FIBRINOLYSIS; HUMAN; NONHUMAN; REVIEW;

EID: 0029943617     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (111)

1. Danø, K., Andreasen, P.A., Grøndahl-Hansen, J., Kristensen, P., Nielsen, L.S., Skriver, L. Plasminogen activators, tissue degradation, and cancer. Adv Cancer Res 1985, 44: 139-266.
2. Danø, K., Behrendt, N., Brünner, N., Ellis, V., Ploug, M., Pyke, C. The urokinase receptor. Protein structure and role in plasminogen activation and cancer invasion. Fibrinolysis 1994, 8: 189-203.
3. Saksela, O., Rifkin, D.B. Cell-associated plasminogen activation: Regulation and physiological functions. Annu Rev Cell Biol 1988, 4: 93-126.
4. Vassalli, J.-D., Sappino A.-P, Belin. D The plasminogen activator/plasmin system. J Clin Invest 1991, 88: 1067-72.
5. Collen, D., Lijnen, H.R. Fibrinolysis and the control of hemostasis. In: The molecular basis of blood diseases. G.S. Stamatoyannopoulos, A.W. Nienhuis, P.W. Majerus, H. Varmus (Eds). W.B. Saunders Co.: Philadelphia, PA 1994, 725-52.
6. Strickland, S., Reich, E. Plasminogen activation in early embryogenesis: Enzyme production by trophoblast and parietal endoderm. Cell 1976, 9: 231-40.
7. Sappino, A.-P, Huarte, J., Belin, D., Vassalli, J.-D. Plasminogen activators in tissue remodeling and invasion: mRNA localization in mouse ovaries and implanting embryos. J Cell Biol 1989, 109: 2471-9.
8. Pepper, M.S., Vassalli, J.-D., Montesano, R., Orci, L. Urokinase-type plasminogen activator is induced in migrating capillary endothelial cells. J Cell Biol 1987, 105: 2535-41.
9. Clowes, A.W., Clowes, M.M., An, Y.P.T., Reidy, M.A., Belin, D. Smooth muscle cells express urokinase during mitogenesis and tissue-type plasminogen activator during migration in injured rat carotid artery. Circ Res 1990, 67: 61-7.
10. Rømer, J., Lund, L.R , Eriksen, J., Pyke, C., Kristensen, P., Danø, K. The receptor for urokinase-type plasminogen activator is expressed by keratinocytes at the leading edge during re-epithelialization of mouse skin wounds. J Invest Dermatol 1994, 102: 519-22.
11. Moscatelli, D., Rifkin, D.B. Membrane and matrix localization of proteases: A common theme in tumor cell invasion and angiogenesis. Biochim Biophys Acta 1988, 948: 67-85.
12. Ossowski, L., Reich, E. Antibodies to plasminogen activator inhibit human tumor metastasis. Cell 1983, 35: 611-9.
13. Mignatti, P., Robbins, E., Rifkin, D.B. Tumor cell invasion through the human amniotic membrane. Requirement for a proteinase cascade. Cell 1986, 47: 487-98.
14. Juhan-Vague, I., Collen, D. On the role of coagulation and fibrinolysis in atherosclerosis. Ann Epidemiol 1992, 2: 427-38.
15. Hamsten, A., Eriksson, P. Fibrinolysis and atherosclerosis: An update. Fibrinolysis 1994, 8 (Suppl. 1): 253-62.
16. Grainger, D.J., Kemp, P.R., Liu, A.C., Lawn, R.M., Medcalfe, J.C. Activation of transforming growth factor-β is inhibited in transgenic apolipoprotein(a) mice. Nature 1994, 370: 460-2.
17. Krystosek, A., Seeds, N.W. Plasminogen activator release at the neuronal growth cone. Science 1981, 213: 1532-4.
18. Sunni, Y., Dent, A.R., Owen, D.E., Seeley, P.S., Morris, R.J. The expression of tissue and urokinase plasminogen activator in neuronal development suggests different models of proteolytic involvement in neuronal growth. Development 1992, 116: 625-37.
19. Qian, Z., Gilbert, M.E., Coticos, M.A., Kandel, E.R., Kuhl, D. Tissue-type plasminogen activator is induced as an immediate-early gene during seizure, kindling and long-term potentiation. Nature 1993, 61. 453-7.
20. Sappino, A.P., Madani, R., Huarte, J. et al. Extracellular roteolysis in the adult murine brain. J Clin Invest 1993, 92: 679-85.
21. Collen, D., Lijnen, H.R. Basic and clinical aspects of fibrinolysis and thrombolysis. Blood 1991, 78 3114-24.
22. Lijnen, H R., Collen, D. Congenital and acquired deficiencies of components of the fibrinolytic system and their relation to bleeding or thrombosis. Fibrinolysis 1989, 3: 67-77.
23. Carmeliet, P., Collen, D. Gene targeting and gene transfer studies of the biological role of the plasminogen/plasmin system. Thromb Haemostas 1995, 74: 429-36.
24. Wun, T.-C., Capuano, A Spontaneous fibrinolysis in whole human plasma. Identification of tissue activator-related protein as the major plasminogen activator causing spontaneous activity in vitro. J Biol Chem 1985, 260. 5061-6.
25. Wun, T.-C., Capuano, A. Initiation and regulation of fibrinolysis in human plasma at the plasminogen activator level. Blood 1987, 69: 1354-62.
26. Gurevich, V. Pro-urokinase: Physiochemical properties and promotion of its fibrinolytic activity by urokinase and by tissue plasminogen activator with which it has a complementary mechanism of action. Semin Thromb Haemostas 1988, 14: 100-15.
27. Brommer, E.J.P. The level of extrinsic plasminogen activator (t-PA) during clotting as a determinant of the rate of fibrinolysis: Inefficiency of activators added afterwards. Thromb Res 1984, 34: 109-15.
28. Zamarron, C., Lijnen, H.R., Collen D. Influence of exogenous and endogenous tissue-type plasminogen activator on the lysability of clots in a plasma milieu in vitro. Thromb Res 1984, 35: 335-45.
29. Fox, K.A.A., Robison, A.K., Knabb, R.M., Rosamond, T.L., Sobel, B.E., Bergmann, S.R. Prevention of coronary thrombosis with subthrombolytic doses of tissue-type plasminogen activator. Circulation 1985, 72: 1346-54.
30. Sprengers, E.D., Kluft, C. Plasminogen activator inhibitors. Biood 1987, 69: 381-7.
31. Loskutoff, D.J., Sawdey, M., Mimuro, J. Type 1 plasminogen activator inhibitor. Prog Haemostas Thromb 1988, 9: 87-115
32. Lecander, I., Roblin, R., Åstedt, B. Differential inhibition of two molecular forms of melanoma cell plasminogen activator by a placental inhibitor. Brit J Haematol 1984, 57: 407-12.
33. Kruithof, E.K.O., Vassalli, J.-D., Schleuning, W.-D., Mattaliano, R J., Bachmann, F. Purification and characterization of a plasminogen activator inhibitor from the histiocytic lymphoma cell line U-937. J Biol Chem 1986, 261: 11207-13.
34. Lecander, I., Åstedt, B. Isolation of a new specific plasminogen activator inhibitor from pregnancy plasma. Brit J Haematol 1986, 62: 221-8.
35. Kruithof, E.K.O., Gudinchet, A., Bachmann, F. Plasminogen activator inhibitor 1 and plasminogen activator inhibitor 2 in various disease states. Thromb Haemostas 1988, 59: 7-12.
36. Declerck, P.J., Juhan-Vague, I., Felez, J., Wiman, B. Pathophysiology of fibrinolysis. J Intern Med 1994, 236: 425-432.
37. Schleef, R.R., Higgins, D.L., Pillemer, E., Levitt, J.J. Bleeding diathesis due to decreased functional activity of type-1 plasminogen activator inhibitor. J Clin Invest 1989, 83: 1747-52.
38. Dieval, J., Nguyen, G., Gross, S., Delobel, J., Kruithof, E.K.O. A lifelong bleeding disorder associated with a deficiency of plasminogen activator inhibitor type-1. Blood 1991, 77: 528-32
39. Fay, W.P., Shapiro, A.D , Shih, J.L., Schleef, R.R., Ginsburg, D. Complete deficiency of plasminogen activator inhibitor type-1 due to a frameshift mutation. New Engl J Med 1992, 327: 1729-33.
40. Erickson, L.A., Fici, G.J , Lund, J.E., Boyle, T.P., Polites, H.G., Marotti, K. R. Development of venous occlusions in mice transgenic for the plasminogen activator inhibitor-1 gene. Nature 1990, 346: 74-6.
41. Carmeliet, P., Kieckens, L., Schoonjans, L. et al. Plasminogen activator inhibitor-1 gene-deficient mice. I. Generation by homologous recombination and characterization. J Clin Invest 1993, 92: 2746-55.
42. Carmeliet, P., Stassen, J.M., Schoonjans, L. et al. Plasminogen activator inhibitor-1 gene-deficient mice. II. Effects on hemostasis, thrombosis and thrombolysis. J Clin Invest 1993, 92: 2756-60.
43. Kuiper, J., Otter, M , Rijken, D.C., Van Berkel, T.J.C. Characterization of the interaction in vivo of tissue-type plasminogen activator with liver cells. J Biol Chem 1988, 263: 18220-4.
44. Devries, S.R., Fox, K.A.A., Robison, A., Rodriguez, U., Sobel, B.E. Determinants of clearance of tissue-type plasminogen activator (t-PA) from the circulation. Fibrinolysis 1987, 1: 17-22.
45. Bounameaux, H., Verstraete, M., Collen, D. Biological and therapeutic properties of new thrombolytic agents. In: Thrombolysis, D. Collen, H.R. Lijnen, M. Verstraete (Eds.) Churchill Livingstone: Edinburgh 1985, 86-91.
46. Narita, M., Bu, G., Herz, J., Schwartz, A.L. Two receptor systems are involved in the plasma clearance of tissue-type plasminogen activator (t-PA) in vivo. J Clin Invest 1995, 96: 1164-8.
47. 2-macroglobulin receptor. Proc Natl Acad Sci USA 1992, 89: 7422-6.
48. 2-macroglobulin receptor is an hepatic receptor for tissue-type plasminogen activator. Proc Natl Acad Sci USA 1992, 89: 7427-31.
49. Kooistra, T., Schrauwen, Y., Arts, J., Emeis, J J. Regulation of endothelial cell t-PA synthesis and release. Int J Hematol 1994, 59: 233-55.
50. Emeis, J.J. The control of t-PA and PAI-1 secretion from the vessel wall. Vasc Med Rev 1995, 6: 153-66.
51. Emeis, J.J. Normal and abnormal endothelial release of tissue-type plasminogen activator. In: Fibrinolysis in Disease. P. Glas-Greenwalt (Ed.). CRC Press: Boca Raton 1995, 55-64.
52. Levin, E.G., Del Zoppo, G.J. Localization of tissue plasminogen activator in the endothelium of a limited number of vessels. Amer J Pathol 1994, 144: 855-61.
53. Kooistra, T. The use of cultured human endothelial cells and hepatocytes as an in vitro model system to study modulation of endogenous fibrinolysis. Fibrinolysis 1990, 4 (Suppl. 2): 33-9.
54. Ny, T., Elgh, F., Lund, B. The structure of the human tissue-type plasminogen activator gene: Correlation of intron and exon structures to functional and structural domains. Proc Natl Acad Sci USA 1984, 81: 5355-9.
55. Fisher, R., Waller, E.K., Grossi, G., Thompson, D., Tizard, R., Schleuning W.-D. Isolation and characterization of the human tissue-type plasminogen activator structural gene including its 5′ flanking region. J Biol Chem 1985, 260: 11223-30.
56. Friezner Degen, S.J., Rajput, B., Reich, E. The human tissue plasminogen activator gene. J Biol Chem 1986. 261: 6972-85.
57. Bulens, F., Ibañez-Tallon, I., Van Acker, P. et al. Retinoic acid induction of human tissue-type plasminogen activator gene expression via a direct repeat element (DR5) located at -7 kilobases. J Biol Chem 1995, 270: 7167-75.
58. Feng, P., Ohlsson, M., Ny, T. The structure of the TATA-less rat tissue-type plasminogen activator gene. Species-specific sequence divergences in the promoter predict differences in regulation of gene expression. J Biol Chem 1990, 265: 2022-7.
59. Rickles, R.J., Darrow, A.L., Strickland, S. Differentiation-responsive elements in the 5′ region of the mouse tissue plasminogen activator gene confer two-stage regulation by retinoic acid and cyclic AMP in teratocarcinoma cells. Mol Cell Biol 1989. 9: 1691-704.
60. Holmberg, M., Leonardsson,G., Ny, T. The species-specific differences in the cAMP regulation of the tissue-type plasminogen activator gene between rat, mouse and human is caused by a one-nucleotide substitution in the cAMP-responsive element of the promoters. Eur J Biochem 1995, 231: 466-74.
61. Levin, E.G., Marzec, U., Anderson, J., Harker, L.A. Thrombin stimulates tissue plasminogen activator release from cultured human endothelial cells. J Clin Invest 1984, 74: 1988-95.
62. Van Hinsbergh, V.W.M., Sprengers, E.D., Kooistra, T Effect of thrombin on the production of plasminogen activators and PA inhibitor-1 by human foreskin microvascular endothelial cells. Thromb Haemostas 1987, 57: 148-53.
63. Hanss, M., Collen, D. Secretion of tissue-type plasminogen activator and plasminogen activator inhibitor by cultured human endothelial cells: modulation by thrombin, endotoxin and histamine. J Lab Clin Med 1987, 109: 97-104.
64. Levin, E.G., Santell, L. Stimulation and desensitization of tissue plasminogen activator release from human endothelial cells. J Biol Chem 1988, 263: 9360-5.
65. Levin, E.G., Marotti, K.R., Santell, L. Protein kinase C and the stimulation of tissue plasminogen activator release from human endothelial cells. Dependence on the elevation of messenger RNA. J Biol Chem 1989, 264: 16030-6.
66. Grülich-Henn, J., Müller-Berghaus, G. Regulation of endothelial tissue plasminogen activator and plasminogen activator inhibitor type 1 synthesis by diacylglycerol, phorbol ester, and thrombin. Blut 1990, 61: 38-44
67. Kooistra, T., Bosma, P.J., Toet, K. et al. Role of protein kinase C and cAMP in the regulation of tissue-type plasminogen activator, plasminogen activator inhibitor 1 and platelet-derived growth factor mRNA levels in human endothelial cells. Possible involvement of protooncogenes c-jun and c-fos. Arteriosclerosis Thromb 1991, 11: 1042-52.
68. Nishizuka, Y. Intracellular signaling by hydrolysis of phospholipids and activation of protein kinase C. Science 1992, 258: 607-14.
69. Hecker, M., Luckhoff, A., Busse, R. Modulation of endothelial autacoid release by protein kinase C: Feedback inhibition or non-specific attenuation of receptor-dependent cell activation? J Cell Physiol 1993, 156: 571-8.
70. Mattila, P., Majuri, M.-J, Tiisala, S., Renkonen, R. Expression of six protein kinase C isotypes in endothelial cells. Life Sci 1994, 55: 1253-60.
71. Bussolino, G., Silvagno, F., Garbarino, G. et al. Human endothelial cells are targets for platelet-activating factor (PAF). J Biol Chem 1994, 269: 2877-86.
72. Santell, L., Levin, E.G. Cyclic AMP potentiates phorbol ester stimulation of tissue plasminogen activator release and inhibits secretion of plasminogen activator inhibitor-1 from human endothelial cells. J Biol Chem 1988, 263: 16802-8.
73. Emeis, J.J., De Vries, R.E.M., Schrauwen, Y., Kooistra, T. Enhancement of endogenous rat plasma tissue-type plasminogen activator antigen and activity by cAMP-enhancing compounds. Fibrinolysis 1994, 8 (Suppl 1):21 (Abst).
74. Kooistra, T., Opdenberg, J.P., Toet, K., Hendriks, H.F.J., Van denHoogen, R.M., Emeis, J.J. Stimulation of tissue-type plasminogen activator synthesis by retinoids in cultured human endothelial cells and rat tissues in vivo Thromb Haemostas 1991, 65: 565-72.
75. Thompson, E.A., Nelles, L., Collen, D. Effect of retinoic acid on the synthesis of tissue-type plasminogen activator and plasminogen activator inhibitor-1 in human endothelial cells. Eur J Biochem 1991, 201: 627-32.
76. Bulens, F., Nelles, L., Van den Panhuyzen, N , Collen, D. Stimulation by retinoids of tissue-type plasminogen activator secretion in cultured human endothelial cells: Relations of structure to effect. J Cardiovasc Pharmacol 1992, 19: 508-14.
77. Medh, R.D., Santell, L., Levin, E.G. Stimulation of tissue plasminogen activator production by retinoic acid: Synergistic effect on protein kinase C-mediated activation. Blood 1992, 80: 981-7.
78. Kooistra, T., Lansink, M., Arts, J., Sitter, T., Toet, K. Involvement of retinoic acid receptor a in the stimulation of tissue-type plasminogen-activator gene expression in human endothelial cells. Eur J Biochem 1995, 232: 425-32.
79. Kooistra, T. The potentials of retinoids as stimulators of endogenous tissue-type plasminogen activator. In: Fibrinoiysis in Disease. P. Glas-Greenwalt (Ed.). CRC PRess: Boca Raton 1995, 237-45.
80. Van Bennekum, A.M., Emeis, J.J., Kooistra, T., Hendriks, H.F.J. Modulation of tissue-type plasminogen activator by retinoids in rat plasma and tissues. Amer J Physiol 1993, 264: R931-7.
81. Wallnöfer, A.E., Van Griensven, J.M.T., Schoemaker, H.C. et al. Effect of isotretinoin on endogenous tissue-type plasminogen activator (t-PA) and plasminogen activator inhibitor 1 (PAI-1) in humans. Thromb Haemostas 1993, 70: 1005-8.
82. Declerck, P.J., Boden, G., Degreef, H., Collen, D. Influence of oral intake of retinoids on the human plasma fibrinolytic system. Fibrinolysis 1993, 7: 347-51.
83. Biesalski, H.K. Comparative assessment of the toxicology of vitamin A and retinoids in man. Toxicology 1989, 57: 117-61.
84. Stunnenberg, H.G. Mechanisms of transactivation by retinoic acid receptors. BioEssays 1993, 15: 309-15.
85. Chambon, P. The retinoid signaling pathway: Molecular and genetic analyses. Semin Cell Biol 1994, 5: 115-25.
86. Nagpal, S., Saunders, M., Kastner, P., Durand, B., Nakshrati, H., Chambon, P. Promoter context- and response element-dependent specificity of the transcriptional activation and modulating functions of retinoic acid receptors. Cell 1992, 70: 1007-19.
87. Chambon, P. The molecular and genetic dissection of the retinoids signalling pathway. Gene 1993, 135: 223-8.
88. Armstrong, R.B., Kim, H.-J., Grippo, J.F., Levin, A.A. Retinoids for the future: Investigational approaches for the identification of new compounds. J Amer Acad Dermatol 1992, 27: S38-42.
89. Kato, S., Mano, H., Kumazawa, T., Yoshizawa, Y., Kojima, R., Masushige, S. Effect of retinoid status on α, β and γ retinoic acid receptor mRNA levels in various rat tissues Biochem J 1992, 286: 755-60.
90. Kooistra, T., Toet, K., Kluft, C. et al. Triazolobenzodiazepines: A new class of stimulators of tissue-type plasminogen activators synthesis in human endothelial cells. Biochem Pharmacol 1993, 46: 61-7
91. Ohta, T., Kikuchi, H., Hashi K., Kudo, Y. Nizofenone administration in the acute stage following subarachnoid hemorrhage. Results of a multi-center controlled double-blind clinical study. J Neurosurg 1986, 64: 420-6.
92. Kooistra, T., Van den Berg, J., Töns, A., Platenburg, G., Rijken, D.C., Van den Berg, E. Butyrate stimulates tissue-type plasminogen-activator synthesis in cultured human endothelial cells. Biochem J 1987, 247: 605-12.
93. Arts, J., Kooistra, T. Studies on the mechanism of sodium butyrate-stimulated t-PA expression in cultured human endothelial cells. Effects of trichostatin A and 2-deoxy-D-glucose. Fibrinolysis 1995, 9: 293-7.
94. Arts, J., Lansink, M., Grimbergen, J., Toet, K.H., Kooistra, T. Stimulation of tissue-type plasminogen activator gene expression by sodium butyrate and trichostatin A in human endothelial cells involves histone acetylation. Biochem J 1995, 310: 171-6.
95. Yoshida, M., Kijima, M., Akita, M., Beppu, T. Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A. J Biol Chem 1990, 265: 17174-9.
96. Novogrodsky, A., Dvir, A., Ravid, A. et al. Effects of polar organic compounds on leukemic cells. Butyrate-induced partial remission of acute myelogenous leukemia in a child. Cancer 1983, 51: 9-14.
97. Miller, A.A., Kurschel, E., Osieka, R., Schmidt, C.G. Clinical pharmacology of sodium butyrate in patients with acute leukemia. Eur J Cancer 1987, 23: 1283-7.
98. Van den Eijnden-Schrauwen, Y., Kooistra, T., De Vries, R.E.M., Emeis, J.J. Studies on the acute release of tissue-type plasminogen activator from human endothelial cells in vitro and in rats in vivo: Evidence fora dynamic storage pool. Blood 1995, 85: 3510-7.
99. Schrauwen, Y., Emeis, J.J., Kooistra, T. A sensitive ELISA for human tissue-type plasminogen activator applicable to the study of acute release from cultured human endothelial cells. Thromb Haemostas 1994, 71: 225-9.
100. Schrauwen, Y., de Vries, R.E M., Kooistra, T., Emeis, J.J. Acute release of tissue-type plasminogen activator (t-PA) from the endothelium: Regulatory mechanisms and therapeutic target. Fibrinolysis 1994, 8 (Suppl. 2): 8-12.
101. Tranquille, N. Pharmacological modulation of the release of tissue-type plasminogen activator and von Willebrand factor. Thesis, University of Leiden, 1991.
102. Klöcking, H.-P. Pharmakologische Beeinflussung der Freisetzung von t-PA aus dem Gefässendothel. Hämostaseologie 1991, 11: 76-92.
103. Emeis, J.J., van den Eijnden-Schrauwen, Y., Kooistra, T. Tissue-type plasminogen activator and the vessel wall: Synthesis, storage and secretion. In: Vascular Control of Haemostasis. V.W.M. van Hinsbergh (Ed.) Gordon and Breach Science Publishers: Victoria 1995, 187-206
104. Van den Eijnden-Schrauwen, Y. Acute release of tissue-type plasminogen activator from human endothelial cells. Thesis, University of Leiden, 1996.
105. Jern, S., Selin, L., Bergbrant, A., Jern, C. Release of tissue-type plasminogen activator in response to muscarinic receptor stimulation in human forearm. Thromb Haemostas 1994, 72: 588-94.
106. Chandler, W.L., Levy, W.C., Stratton, J.R. The circulatory regulation of t-PA and u-PA during exercise and alpha- and beta-adronergic agonist infusions. Fibrinolysis 1994, 8 (Suppl. 1): 13 (Abst).
107. Neer, E.J Heterotrimeric G-proteins: Organizers of transmembrane signals. Cell 1995, 80. 249-57.
108. Vane, J.R., Änggard, E.E., Botting, R.M. Regulatory function of the vascular endothelium. New Engl J Med 1990, 323: 27-36.
109. Carter, T.D., Pearson, J.D. Regulation of prostacyclin synthesis in endothelial cells. News Physiol Sci 1992, 7: 64-9.
110. Birch, K.A., Ewenstein, B.M., Golan, D.E , Pober, J.S. Prolonged peak elevations in cytoplasmic free calcium ions, derived from intracellular stores, correlate with the extent of thrombin-stimulated exocytosis in single human umbilical vein endothelial cells. J Cell Physiol 1994, 160: 545-54
111. Frearson, J.A., Harrison, P., Scrutton, M.C., Pearson, J.D. Differential regulation of von Willebrand factor exocytosis and prostacyclin synthesis in electropermeabilized endothelial cell monolayers. Biochem J 1995, 309. 473-9.